MYGNMyriad Genetics, Inc.

Quick Summary

Myriad Genetics, Inc. is a molecular diagnostics company based in Salt Lake City, Utah. The company develops and commercializes genetic tests used primarily in oncology, women’s health, and mental health. Its products help physicians, health systems, and patients assess hereditary cancer risk, guide treatment decisions, monitor disease, and evaluate medication-response considerations. Its main customers include oncologists, OB/GYNs, genetic counselors, psychiatrists, hospitals, reference laboratories, insurers, and patients who receive testing through medical providers. The company operates in the pharmaceutical products and diagnostics-related segment, but its business model is centered on laboratory testing services rather than drug development. Myriad’s revenue depends heavily on test volumes, reimbursement coverage, clinical adoption, regulatory compliance, and its ability to introduce newer precision-medicine tests.

Key Risks

• Myriad faces regulatory risk because genetic tests and clinical claims can attract scrutiny from agencies such as the FDA.
• GeneSight has historically faced questions about clinical claims, and renewed regulatory or reimbursement pressure could hurt volume or pricing.
• Reimbursement risk is significant because payer coverage decisions strongly influence patient access and test profitability.
• Competitive risk is also high, as companies such as Natera, Guardant Health, Exact Sciences, Labcorp, Quest, and others are active in overlapping diagnostics markets.

What to Watch

Price Drivers

• MYGN’s stock price is likely driven by revenue growth, test-volume trends, reimbursement developments, margin performance, cash flow, and progress toward profitability.
• The company reported negative basic and diluted EPS of -0.46 and net income of -$43.2 million, so investors are sensitive to signs that losses are narrowing.
• Recent quarter news showed revenue fell 4% to $205.7 million, but also highlighted adjusted EBITDA of $10.3 million and free cash flow of $18.6 million, which can support investor confidence if sustained.
• Guidance is another major driver, with recent updates pointing to 2025 revenue of roughly $818 million to $828 million and 2026 revenue expectations of $860 million to $880 million.

Recent News

• Recent news showed that Myriad Genetics reported Q3 revenue down 4% to $205.7 million, with adjusted gross margin of 70.1%.
• The company also reported adjusted EBITDA of $10.3 million and free cash flow of $18.6 million, which were important indicators of operating performance.
• Segment trends were mixed, with Oncology down 1%, Women’s Health up 3%, and GeneSight volume up 8%.
• MyRisk and hereditary cancer testing showed strong volume gains, suggesting that the core hereditary cancer franchise remains active.

Market Trends

• The broader market backdrop is favorable for genetic testing, personalized medicine, oncology diagnostics, and women’s health testing.
• Personalized medicine is projected to grow strongly as genomics, biotechnology, lower sequencing costs, and data analytics become more embedded in clinical care.
• Liquid biopsy is expected to expand as non-invasive cancer detection, treatment monitoring, and early screening gain clinical and commercial traction.
• Women’s health laboratory testing is also benefiting from greater awareness of hereditary cancer, prenatal testing, reproductive health, and infection screening.